Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202245 | 0.83 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL29617524 | 0.83 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL30253490 | 0.83 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL21838309 | 0.78 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL9009565 | 0.78 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL13327274 | 0.75 | POLB (0.52) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL22397770 | 0.75 | POLB (0.52) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL16424441 | 0.73 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL5497604 | 0.73 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7139454 | 0.73 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113305-A1 | OXAZOLE AND THIAZOLE COMBINATORIAL LIBRARIES | BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20060161007-A1 | Oxazole and thiazole combinatorial libraries | M MARTIN LENORE | 2006-07-20 | — | — | US | disclosed |
| EP-1169311-A4 | OXAZOLE AND THIAZOLE COMBINATORIAL LIBRARIES | RHODE ISLAND EDUCATION (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1169311-A1 | OXAZOLE AND THIAZOLE COMBINATORIAL LIBRARIES | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000056724-A9 | OXAZOLE AND THIAZOLE COMBINATORIAL LIBRARIES | RHODE ISLAND EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000056724-A1 | OXAZOLE AND THIAZOLE COMBINATORIAL LIBRARIES | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113305-A1 | OXAZOLE AND THIAZOLE COMBINATORIAL LIBRARIES | OXA1L, SPOUT1, BCAT2 | KMT2A 2233/4885FABP5 3068/4885FABP7 2372/4885 |
| US-20060161007-A1 | Oxazole and thiazole combinatorial libraries | OXA1L, SPOUT1, BCAT2 | KMT2A 2233/4885FABP5 3068/4885FABP7 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.